Difference between revisions of "Part:BBa K1621004:Design"
m (→References) |
m (→Design Notes) |
||
| Line 7: | Line 7: | ||
===Design Notes=== | ===Design Notes=== | ||
| − | The sequence was codon optimized for expression in | + | The sequence was codon optimized for expression in ''Escherichia coli'' with the codon optimization tool from IDT. |
| − | + | ||
| − | + | ||
===Source=== | ===Source=== | ||
Latest revision as of 09:30, 30 August 2015
gag/tat/pol/env - polyepitopic antigen derived from HIV-1
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
Design Notes
The sequence was codon optimized for expression in Escherichia coli with the codon optimization tool from IDT.
Source
The sequence for this part was obtained from Jafarpour et al. (2014) and synthesized by Integrated DNA Technologies.
References
Goepfert PA (2003). Making sense of the HIV immune response. Top HIV Med 11(1):4–8.
Jafarpour N, Memarnejadian A, Aghasadeghi MR, Kohram F, Aghababa H, Khoramabadi N, Mahdavi M (2014). Clustered epitopes within a new poly-epitopic HIV-1 DNA vaccine shows immunogenicity in BALB/c mice. Mol Biol Rep 41:5207–5214.
Memarnejadian A, Roohvand F, Arashkia A, Rafati S, Shokrgozar MA (2009). Polytope DNA vaccine development against hepatitis C virus: a streamlined approach from in silico design to in vitro and primary in vivo analyses in BALB/c mice. Protein Pept Lett 16(7):842–850.